Independent. No paid placement. Reviewed weekly Editorial policy Newsletter

Home›The Library›Telavancin

Telavancin

Written by The Peptide Record editorialClinical review not yet completedLast reviewed 19 September 2026

Telavancin (Vibativ) is a real, FDA-approved semi-synthetic descendant of vancomycin — a lipoglycopeptide antibiotic with a genuinely heavier label than its parent drug, including a specific boxed warning about birth defects seen in animal studies.

On this page
  1. A dual-mechanism descendant of vancomycin
  2. The approval and pivotal trials
  3. A three-part boxed warning
  4. Current status

In brief

Should you care? Relevant only in hospital-level gram-positive infection treatment — no wellness angle.

The short version

  • A semi-synthetic vancomycin derivative with an added lipid tail, giving it a second, membrane-disrupting mechanism vancomycin itself doesn't have.
  • Approved 2009 for complicated skin infections, based on the ATLAS trial program.
  • Three-part boxed warning: increased mortality in patients with pre-existing kidney impairment, new kidney injury risk, and teratogenicity shown in three animal species.

A dual-mechanism descendant of vancomycin

Telavancin is a semi-synthetic lipoglycopeptide, chemically derived from vancomycin with an added lipophilic side chain. Like vancomycin, it blocks bacterial cell-wall synthesis by binding the D-Ala-D-Ala terminus of peptidoglycan precursors — but the added lipid tail lets it additionally insert into and disrupt the bacterial cell membrane directly, a second mechanism vancomycin itself lacks, contributing to more rapid bactericidal killing.

The approval and pivotal trials

The FDA approved telavancin (as Vibativ) on 11 September 2009 for complicated skin and skin-structure infections, based on the ATLAS trial program (Stryjewski et al., Clin Infect Dis 2008, PMID 18444791): two parallel trials in 1,867 patients comparing telavancin to vancomycin. A supplemental approval for hospital-acquired and ventilator-associated bacterial pneumonia followed, based on the ATTAIN trial program (Rubinstein et al., Clin Infect Dis 2011, PMID 21148517).

A three-part boxed warning

Telavancin carries a genuinely heavier label than vancomycin itself: a boxed warning covering (1) increased mortality in patients with pre-existing moderate-to-severe kidney impairment treated for hospital-acquired pneumonia, compared to vancomycin; (2) new-onset or worsening kidney injury, requiring monitoring in all patients; and (3) teratogenicity — adverse developmental effects shown in three separate animal species at clinically relevant doses, with the label requiring a pregnancy test before dosing in women of childbearing potential. This is one of the more heavily-boxed antibiotics on this site.

Current status

Still commercially available, currently marketed by Cumberland Pharmaceuticals. Hospital-only IV use, no wellness or grey-market presence.

References

  1. Stryjewski ME, Chu VH, O'Riordan WD, et al. (ATLAS Randomized Trials), "Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms," Clin Infect Dis 2008;46(11):1683-1693, PMID 18444791.
  2. Rubinstein E, Lalani T, Corey GR, et al. (ATTAIN Study Group), "Telavancin versus Vancomycin for Hospital-Acquired Pneumonia Due to Gram-Positive Pathogens," Clin Infect Dis 2011;52(1):31-40, PMID 21148517.
  3. FDA approval history for Vibativ (telavancin), 11 September 2009.